Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 3 - Drugs for disorders of the metabolism
Patents for A61P 3 - Drugs for disorders of the metabolism (129,789)
11/2009
11/03/2009US7612110 Immunosuppressants; for use in transplantation medicine or treatment of autoimmune diseases such as polyarthritis but not psoriatitc arthritis; micro-tablets, pellets
11/03/2009US7612092 Nitrogen-containing aromatic derivatives
11/03/2009US7612090 Use in treatment of a disorder which is created by or is dependent upon decreased availability of serotonin, norepinephrine or dopamine
11/03/2009US7612058 Administering 1-(4-fluorophenyl)-3(R)-[3(S)-(4-fluorophenyl)-3-hydroxypropyl)]-4(S)-[4-(phenylmethoxy)phenyl]-2-azetidinone; and peroxisome proliferator-activated receptor activator; obesity, antidiabetic agents
11/03/2009US7612033 administering to the cell a composition which comprises the compound to be delivered and an organic halide such as a perfluorocarbon; ultrasound
11/03/2009US7611729 Dosage forms having prolonged active ingredient release
11/03/2009CA2448035C New pharmaceutical composition
11/03/2009CA2443724C Novel, arylsusfonamide compounds for the treatment of obesity, type ii diabetes and cns-disorders
11/03/2009CA2407421C Activators of peroxisome proliferator-activated receptors
11/03/2009CA2383220C Controlled release pellet formulation
11/03/2009CA2372668C Novel use of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine and its physiologically acceptable salts
11/03/2009CA2353133C Treatment of disorders secondary to organic impairments
11/03/2009CA2324283C Pharmaceutical composition containing a statin and aspirin
11/03/2009CA2320991C Calorically dense nutritional composition
10/2009
10/29/2009WO2009132136A1 Carboxamide compounds for the treatment of metabolic disorders
10/29/2009WO2009131191A1 Metastin derivative and use thereof
10/29/2009WO2009131171A1 Novel five-membered ring compound
10/29/2009WO2009131170A1 Five-membered ring compound
10/29/2009WO2009131096A1 Compound having npy y5 receptor antagonist activity
10/29/2009WO2009131065A1 Long-chain fatty acid elongation enzyme inhibitor comprising arylsulfonyl derivative as active ingredient
10/29/2009WO2009130496A1 Substituted pyrimidin-5-carboxamides 281
10/29/2009WO2009130422A2 N-acylthiourea and n-acylurea inhibitors of the hedgehog protein signalling pathway
10/29/2009WO2009129726A1 Nitrone compounds, process of preparation thereof, and use thereof in medicament manufacture
10/29/2009WO2009129696A1 A kind of receptor signaling transoluction positive modulators, preparation methods and uses thereof
10/29/2009WO2009111239A3 Pyrrolidine derivatives
10/29/2009WO2009111078A3 Combination of a ppary agonist and a dipeptidyl peptidase-inhibitor for the treatment of diabetes and obesity
10/29/2009WO2009105504A3 Functionally selective alpha2c adrenoreceptor agonists
10/29/2009WO2009093208A3 Substituted 2-amino-3-sulfonyl-pyrazolo[1,5-a] pyrimidines/antagonists of serotonin 5-ht6 receptors, methods for the production and the use thereof
10/29/2009WO2009093206A3 3-sulfonyl-pyrazolo[1,5-a] pyrimidines / antagonists of serotonin 5-ht6 receptors, methods for the production and the use thereof
10/29/2009WO2009046856A3 Use of serorphin as a therapeutic agent
10/29/2009WO2009046824A3 Use of apelin-12 as a therapeutic agent, eg for treating excessive angiogenesis
10/29/2009WO2009043505A3 Use of beta-melanotropin as a therapeutic agent, eg for the treatment of aids or alzheimer
10/29/2009WO2009043504A3 Use of apelin-36 and optionally beta-melanotropin as therapeutic agents, eg for treating aids or alzheimer
10/29/2009WO2009040089A3 Use of the peptides maippkknqdk (cow kappa casein 106-116) and/or ygfqna (serorphin) as therapeutic agents
10/29/2009WO2009039996A3 Use of bradykinin alone or in combination with melanotan ii as a therapeutic agent
10/29/2009WO2009039977A3 Use of alpha-casein (90-96) as a therapeutic agent in eg the treatment of hbv infection
10/29/2009WO2009033781A3 Use of k237 as therapeutic agent
10/29/2009WO2009033751A3 Use of leu-enkephalin as a therapeutic agent
10/29/2009WO2009033718A3 Use of anti -inflammatory peptide 1 as a therapeutic agent
10/29/2009WO2009020802A3 Use of an fgf-21 compound and a glp-1 compound for the treatment of obesity
10/29/2009WO2009009173A3 Klotho-beta for use in treating cancer, liver disorders, gallstones, wasting syndrome and obesity-related diseases
10/29/2009US20090270506 Crystalline structure of oxidosqualene synthase
10/29/2009US20090270503 Nutritional supplements
10/29/2009US20090270500 4-trimethylammonio-butyrates as cpt2 inhibitors
10/29/2009US20090270489 Long-acting polypeptides and methods of producing same
10/29/2009US20090270468 Preparation and use of aryl alkyl acid derivatives for the treatment of obesity
10/29/2009US20090270467 5-[(1S,3S,4R)-3-Amino-4-(2,4,5-trifluorophenyl)cyclohexyl]-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-amine, used for treating insulin resistance, hyperglycemia and non-insulin dependent diabetes in mammals
10/29/2009US20090270464 Benzimidazole derivative and use as a II receptor antagonist
10/29/2009US20090270458 Method of treating of demyelinating diseases or conditions
10/29/2009US20090270436 Spirochromanon derivatives
10/29/2009US20090270435 Spiroketone Acetyl-CoA Carboxylase Inhibitors
10/29/2009US20090270434 Azacycloalkane derivatives as inhibitors of stearoyl-coenzyme a delta-9 desaturase
10/29/2009US20090270427 Purine derivatives
10/29/2009US20090270403 Novel 1,4-diaza-bicyclo[3.2.2]nonyl pyrimidinyl derivative and its medical use
10/29/2009US20090270388 Fused azole-pyrimidine derivatives
10/29/2009US20090270382 Soluble epoxide hydrolase inhibitors
10/29/2009US20090270372 Melanocortin receptor MC4 modulators; obesity, sexual disorders, anxiolytic agents, analgesics, antidepressants; 6-(aminomethyl)-2-aminobenzimidazole derivatives
10/29/2009US20090270331 Multi-domain amphipathic helical peptides and methods of their use
10/29/2009US20090269415 Novel therapeutic agent derived from marine organism
10/29/2009US20090269337 Compositions and methods for treating diabetes
10/29/2009US20090269332 Human diacylglycerol acyltransferase 2 (DGAT2) family members and uses therefor
10/29/2009US20090269322 Compositions comprising selenium-rich yeast and yeast beta-glucan
10/29/2009US20090269313 Encapsulation system
10/29/2009CA2759833A1 Immunoisolation patch system for cellular transplantation
10/29/2009CA2722258A1 N-acylthiourea and n-acylurea inhibitors of the hedgehog protein signalling pathway
10/29/2009CA2722139A1 Carboxamide compounds for the treatment of metabolic disorders
10/29/2009CA2722075A1 Long-chain fatty acyl elongase inhibitor comprising arylsulfonyl derivative as active ingredient
10/29/2009CA2722041A1 Novel five-membered ring compound
10/29/2009CA2722007A1 Five-membered ring compound
10/29/2009CA2721576A1 Compound having npy y5 receptor antagonist activity
10/29/2009CA2720681A1 Neutralizing proprotein convertase subtilisin kexin type 9 (pcsk9) variants and uses thereof
10/29/2009CA2719936A1 Substituted pyrimidin-5-carboxamides 281
10/28/2009EP2112161A2 Peptides that lower blood glucose levels
10/28/2009EP2112151A2 Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith
10/28/2009EP2112134A1 Carboxylic acids and derivatives thereof and pharmaceutical compositions containing them
10/28/2009EP2111865A1 Utilization of the function of rare sugar as promoter for the migration of glucokinase from nucleus to cytoplasm
10/28/2009EP2111859A1 5HT2C receptor modulator compositions and methods of use
10/28/2009EP2111406A1 Substituted spirochromanone derivatives as acc inhibitors
10/28/2009EP2111395A1 New phenyl- (4-phenyl-pyrimidin-2-yl) - amines derivatives, preparation thereof as drugs, pharmaceutical compositions and use thereof essentially as ikk inhibitors
10/28/2009EP2111225A2 Inhibition of ppar gamma expression by specific osteogenic oxysterols
10/28/2009EP1828207B1 Thiazolopyridinone derivates as mch receptor antagonists
10/28/2009EP1734959B1 Compounds for treating schizophrenia and/or glucoregulatory abnormalities
10/28/2009EP1660066B1 Pharmaceutical composition comprising a combination of metformin and a statin
10/28/2009EP1548032B9 Kdr peptides and vaccines comprising the same
10/28/2009EP1379504B1 Bipiperidinyl-derivatives and their use as chemokine receptors inhibitors
10/28/2009EP1181047B2 Composition comprising alkaline sphingomyelinase of bacterial origin for use as a dietetic preparation, food supplement or pharmaceutical product
10/28/2009EP0915706B1 Screening methods for compounds useful in the regulation of body weight
10/28/2009CN101568552A Collagen peptide composition and food or beverage containing the same
10/28/2009CN101568537A Method for producing C-glycoside derivative and synthetic intermediate thereof
10/28/2009CN101568525A Cb1 receptor modulators
10/28/2009CN101568361A Use of nutritional compositions for preventing disorders
10/28/2009CN101568334A Iron metabolism-improving agent
10/28/2009CN101565429A Inhibitors of dipeptidylpeptidase iv
10/28/2009CN101565411A Method for extracting fucoxanthin from brown algae
10/28/2009CN101565408A Receptor signal transduction positive modulator, preparation method and purpose thereof
10/28/2009CN101565394A Crystalline forms of atorvastatin
10/28/2009CN101565385A Pigling intestinal tract nutrition regulation and control substance N-carbamoylglutamine and preparation method
10/28/2009CN101565376A Method for extracting natural octopamine
10/28/2009CN101564532A Four-scheme medicine preparing method
10/28/2009CN101564511A Natural protein product for treating diabetes and manufacture method
1 ... 391 392 393 394 395 396 397 398 399 400 401 402 403 404 405 406 407 408 409 410 411 ... 1298